Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on May 21, 2019, regarding events occurring on May 20, 2019. The filing primarily addresses a material change in executive leadership and the entry into a new employment agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details rather than periodic financial performance.
Material Changes
- Executive Leadership Transition: The Board appointed Dror Bashan as the new President and Chief Executive Officer, effective June 30, 2019. He will also join the Board of Directors.
- Departure of Current CEO: Mr. Manor is stepping down as President and CEO for personal reasons but will assist with the transition and continue as a consultant.
- Compensation Structure: Mr. Bashan's employment agreement includes a monthly base salary of 95,000 New Israeli Shekels (approximately $26,600), an annual discretionary bonus, and a one-time bonus of $1,000,000 upon a change of control.
- Equity Grant: Mr. Bashan was granted options to purchase 1,600,000 shares of common stock, vesting over four years on a quarterly basis.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, market outlook, or specific risk factors beyond the standard terms of the employment agreement. The agreement is terminable by the Company on 180 days' written notice and by Mr. Bashan on 90 days' written notice. Vesting of stock options accelerates in full upon a Corporate Transaction or Change in Control.
Investor Verification Checklist
- Verify the exact closing stock price on the trading day preceding June 30, 2019, to determine the exercise price of the 1,600,000 stock options granted to Mr. Bashan.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Change of Control" and "Corporate Transaction."
- Confirm the transition timeline and the specific scope of Mr. Manor's ongoing consultant role.
- Monitor future filings for the formal resignation of Mr. Manor and the official start of Mr. Bashan's tenure on June 30, 2019.